PD-L1 expression

1:44
The role of the pathologist in the field of lung cancer
Keith Kerr
3:37
Problems with PD-L1 expression testing in patients with NSCLC
Keith Kerr
2:10
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
Federico Cappuzzo
1:28
ATLANTIC: durvalumab in the fight against NSCLC
Marina Garassino
1:14
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
David Carbone
4:20
Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151
Toni Choueiri
1:13
Guiding NSCLC treatment with biomarkers
Alastair Greystoke
2:18
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
Thomas Powles
3:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Jacob Kettle
1:18
Checkpoint inhibitors in small cell lung cancer (SCLC)
David Spigel
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals